Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen
Launched by LABO'LIFE · Feb 23, 2016
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
The primary objective of this study is to demonstrate the superiority of 2L®ALERG over placebo in terms of efficacy on the symptoms of allergic rhinitis and allergic rhinoconjunctivitis in patients with seasonal allergy to grass pollen, corrected according to rescue medication intake. The secondary objectives are to compare the allergy symptoms, the rescue medication intake, the quality of life and the safety in patients treated with 2L®ALERG or with a placebo.
This is a multicentre, randomized, double-blind, two-parallel group, interventional placebo-controlled study with a notified homeo...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years, male and female
- • Woman of childbearing age using effective contraceptive means
- • Patient having the faculties to understand and respect the constraints of the study
- • Symptomatic since at least two seasons and confirmed by positive skin test and/or the presence of IgE for grasses (prick test defined as positive if higher than or equal to half the negative control; IgE positive if at least class 3 (≥ 3.5 kU / L); these tests must have been performed at the latest at the first screening visit
- • Signature of the Informed Consent Form
- Exclusion Criteria:
- • Pregnant woman or woman wishing to become pregnant
- • Breastfeeding woman
- • Patient with an acute exacerbation of allergic rhinitis
- • Patient with uncontrolled asthma
- • Immunotherapy received within the last two years
- • Patient with a known lactose intolerance
- • Patient who participated in a clinical study in the previous three months
- • Patient who is not sufficiently motivated to engage on a follow-up period of 6 months or more, unable to complete the patient diary, or likely to travel or to move before the end of the study,
- • Patient taking nasal or bronchial inhaled corticosteroids on a long term basis (intermittent consumption during the season is permitted provided it is mentioned in the patient's records)
About Labo'life
labo'life is a forward-thinking clinical trial sponsor dedicated to advancing healthcare through innovative research and development. With a focus on improving patient outcomes, labo'life specializes in conducting robust clinical trials across various therapeutic areas, leveraging cutting-edge technologies and methodologies. Committed to ethical practices and regulatory compliance, the organization collaborates closely with healthcare professionals, regulatory authorities, and patients to ensure the highest standards of safety and efficacy in its studies. By fostering a patient-centered approach, labo'life aims to contribute significantly to the advancement of medical knowledge and the development of novel therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Linkebeek, , Belgium
Patients applied
Trial Officials
Stéphane Heijmans, MD
Principal Investigator
ResearchLink
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials